Expedition Therapeutics Achieves Major Funding Milestone with $115 Million Series B Investment
Expedition Therapeutics Secures $115 Million Series B Funding
In a groundbreaking development for the biopharmaceutical sector, Expedition Therapeutics has successfully raised $115 million in a Series B funding round. This substantial investment not only underscores the confidence investors have in the company’s innovative approach but also positions them to further advance their clinical pipelines focused on respiratory diseases.
Expedition Therapeutics, founded by Yi Larson, specializes in the development of transformative therapies aimed at treating chronic obstructive pulmonary disease (COPD) and other similar ailments through the utilization of novel compounds. With this recent capital influx, the company is expected to accelerate its clinical trials, specifically the Phase 2 trials of EXPD-101, which represent a significant step forward in the fight against COPD.
During an NYSE Live session following the announcement, Yi Larson expressed her excitement, stating that this funding will allow the company to
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.